Companies Omeros Corp
Omeros (OMER): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Omeros Corp’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers75th pct.Of 12 peer CEOs
CEO pay, last three years
- $7,689,843FY2023
- $3,764,151FY2024
- $4,178,008FY2025
CEO total pay was $4,178,008 in fiscal 2025, up from $3,764,151 in fiscal 2024.
FY2025: salary $972,525 · bonus $972,525 · stock awards $0 · option awards $2,207,974
Executives and directors
David Borges · ExecutivePeter Cancelmo · General CounselGregory Demopulos · CEOArnold C. Hanish · Independent DirectorDiana T. Perkinson, M.D · Independent DirectorLeroy E. Hood, M.D., Ph.D · Independent DirectorPeter A. Demopulos, M.D · DirectorRajiv Shah, M.D · Independent DirectorThomas F. Bumol, Ph.D · Independent DirectorThomas J. Cable · Lead Independent Director
Frequently asked questions
Who was the highest-paid executive at Omeros Corp in fiscal 2025?
As disclosed, Gregory Demopulos (President, Chief Executive Officer and Chairman of the Board) was the highest-paid executive at Omeros Corp in fiscal 2025, with total compensation of $4,178,008.
How does Omeros Corp's chief executive pay compare to its disclosed peer group?
As disclosed, Gregory Demopulos's total compensation ranked at the 75th percentile of Omeros Corp's disclosed peer group.
What is Omeros Corp's CEO-to-median employee pay ratio?
As disclosed, Omeros Corp's CEO-to-median employee pay ratio was 21.8:1.
How did shareholders vote on Omeros Corp's executive compensation?
As disclosed, 78.05% of shareholders supported Omeros Corp's executive compensation in the latest say-on-pay vote.
How much does Omeros Corp spend in total on board compensation for fiscal 2025?
As disclosed, Omeros Corp reported total board compensation of $495,000 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Gregory Demopulos | $972,525 | $972,525 | $0 | $2,207,974 | $0 | $0 | $24,984 | $4,178,008 |
| President, Chief Executive Officer and Chairman of the Board | ||||||||
| Peter Cancelmo | 489,480 | 171,318 | 0 | 255,257 | 0 | 0 | 4,647 | 920,702 |
| Vice President, General Counsel and Secretary | ||||||||
| David Borges | 325,600 | 113,750 | 0 | 242,494 | 0 | 0 | 4,430 | 686,274 |
| Vice President, Finance, Chief Accounting Officer and Treasurer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Gregory Demopulos | $4,178,008 | $3,764,151 | $7,689,843 | ↑ +413,857 |
| Peter Cancelmo | 920,702 | 906,894 | 852,633 | ↑ +13,808 |
| David Borges | 686,274 | 627,907 | — | ↑ +58,367 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Omeros offers competitive compensation and benefits packages focused on creating long-term shareholder value and rewarding executives for achieving strategic objectives. The program aims to recruit and retain skilled executives, align executive interests with shareholders, and create a direct link between company business results, individual performance, and compensation.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Compensia |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Gregory Demopulos | OPTION | 2025-06-30 | — | — | 865,000 | — | $2,207,974 |
| David Borges | OPTION | 2025-06-30 | — | — | 95,000 | — | 242,494 |
| Peter Cancelmo | OPTION | 2025-06-30 | — | — | 100,000 | — | 255,257 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Gregory Demopulos | $0 | $0 | $2,207,974 | 0.0% |
| David Borges | 0 | 0 | 242,494 | 0.0% |
| Peter Cancelmo | 0 | 0 | 255,257 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| David Borges | Option | 1,667 | 3.93 | — |
| Peter Cancelmo | Option | 6,667 | 3.93 | — |
| David Borges | Option | 8,333 | 2.94 | — |
| Peter Cancelmo | Option | 33,333 | 2.94 | — |
| Gregory Demopulos | Option | 54,167 | 3.93 | — |
| David Borges | Option | 55,417 | 3.06 | — |
| Peter Cancelmo | Option | 58,333 | 3.06 | — |
| David Borges | Option | 79,167 | 3.2 | — |
| Peter Cancelmo | Option | 83,333 | 3.2 | — |
| Gregory Demopulos | Option | 238,333 | 2.94 | — |
| Gregory Demopulos | Option | 422,917 | 3.06 | — |
| Gregory Demopulos | Option | 720,833 | 3.2 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Thomas J. CableIndependent · Lead Independent Director · AUDIT COMMITTEE · COMPENSATION COMMITTEE (Chair) · NOMINATING AND GOVERNANCE COMMITTEE (Chair) | $110,000 | $0 | $41,060 | — | $0 | $151,060 |
| Rajiv Shah, M.DIndependent · Audit · Compensation · Scientific | 72,500 | 0 | 41,060 | — | 0 | 113,560 |
| Arnold C. HanishIndependent · AUDIT COMMITTEE (Chair) | 70,000 | 0 | 41,060 | — | 0 | 111,060 |
| Leroy E. Hood, M.D., Ph.DIndependent · Compensation · Nominating and Governance · Scientific | 67,500 | 0 | 41,060 | — | 0 | 108,560 |
| Thomas F. Bumol, Ph.DIndependent · Scientific (Chair) | 60,000 | 0 | 41,060 | — | 0 | 101,060 |
| Diana T. Perkinson, M.DIndependent · Nominating and Governance · Scientific | 60,000 | 0 | 41,060 | — | 0 | 101,060 |
| Peter A. Demopulos, M.DNot independent · Scientific | 55,000 | 0 | 41,060 | — | 0 | 96,060 |
| Gregory A. Demopulos, M.DEmployee director · Board Chair | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $495,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $495,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Omeros as a peer
Companies that benchmark against OMER
4 companies name OMER as a compensation peer
The list of companies that name OMER as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
AGIO Agios Pharmaceuticals, Inc.RCUS Arcus Biosciences, Inc.COLL Collegium Pharmaceutical,ENTA Enanta Pharmaceuticals, Inc.ESPR Esperion Therapeutics, Inc.IRWD Ironwood Pharmaceuticals, Inc.KPTI Karyopharm TherapeuticsMRSN Mersana Therapeutics, Inc.PCRX Pacira BioSciences, Inc.VNDA Vanda Pharmaceuticals, Inc.CHRS Coherus BioSciences, Inc.ACRS Aclaris Therapeutics, Inc.
Peer reciprocity
The companies Omeros Corp names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Pacira BioSciences, Inc. | 2025 | Frank Lee | $935,308 | $9,215,500 | $0 | $738,810 | $11,636,917 |
| 2 | Arcus Biosciences, Inc. | 2025 | Terry Rosen | 775,000 | 2,199,450 | 6,008,860 | 658,750 | 9,656,813 |
| 3 | Agios Pharmaceuticals, Inc. | 2025 | Brian Goff | 846,864 | 1,291,680 | 2,627,252 | 592,804 | 5,370,389 |
| 4 | Omeros Corp | 2025 | Gregory Demopulos | 972,525 | 0 | 2,207,974 | 0 | 4,178,008 |
| 5 | Vanda Pharmaceuticals, Inc. | 2025 | Mihael Polymeropoulos | 965,655 | 2,007,000 | 0 | 834,326 | 3,851,468 |
| 6 | Esperion Therapeutics, Inc. | 2025 | Sheldon Koenig | 770,833 | 1,260,000 | 847,929 | 639,375 | 3,535,512 |
| 7 | Aclaris Therapeutics, Inc. | 2025 | Neal Walker | 615,000 | 828,426 | 1,581,615 | 350,550 | 3,375,591 |
| 8 | Enanta Pharmaceuticals, Inc. | 2025 | Jay Luly | 803,300 | 128,550 | 1,223,975 | 591,665 | 2,769,548 |
| 9 | Coherus BioSciences, Inc. | 2025 | Dennis Lanfear | 1,026,545 | 0 | 828,130 | 869,295 | 2,736,874 |
| 10 | Karyopharm Therapeutics | 2025 | Richard Paulson | 770,000 | 838,996 | 241,544 | 350,350 | 2,320,902 |
| 11 | Ironwood Pharmaceuticals, Inc. | 2025 | Thomas McCourt | 867,568 | 411,696 | 0 | 650,676 | 1,948,390 |
| 12 | Collegium Pharmaceutical, | 2025 | Vikram Karnani | 875,000 | 0 | 0 | 835,406 | 1,715,846 |
| 13 | Mersana Therapeutics, Inc. | 2024 | Michael Huber | 632,500 | 133,635 | 518,044 | 322,575 | 1,613,754 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Omeros Corp | not disclosed | Option 100 | not disclosed | Compensia |
| Aclaris Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Pearl Meyer |
| Agios Pharmaceuticals, Inc. | 100% | Option 40 · PSU 40 · RSU 20 | No | Aon |
| Arcus Biosciences, Inc. | 100% | Options 67 · RSU 33 | not disclosed | Radford |
| Coherus BioSciences, Inc. | not disclosed | Option 100 | not disclosed | Aon |
| Collegium Pharmaceutical, | 127.3% | RSU 70 · PSU 30 | Yes — relative ranking of the total shareholder return (TSR) of the Company's common stock in 2025, 2026, 2027 and the cumulative three-year performance period (2025-2027) return relative to the TSR of peer companies within the S&P Pharmaceutical Select Industry Index | Alpine Rewards, LLC |
| Enanta Pharmaceuticals, Inc. | not disclosed | Options 80 · PSU 10 · MSU 10 | No | Alpine Rewards LLC |
| Esperion Therapeutics, Inc. | 110% | not disclosed | not disclosed | not disclosed |
| Ironwood Pharmaceuticals, Inc. | 100% | RSU 50 · PSU 50 | not disclosed | Alpine Rewards LLC |
| Karyopharm Therapeutics | 90% | not disclosed | Yes — Relative TSR | Alpine, WTW |
| Mersana Therapeutics, Inc. | not disclosed | Option 75 · RSU 25 | not disclosed | Pearl Meyer & Partners, LLC |
| Pacira BioSciences, Inc. | 90% | RSU 80 · PSU 20 | No | Aon |
| Vanda Pharmaceuticals, Inc. | 108% | not disclosed | Yes — Relative TSR | Willis Towers Watson |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-18 | 24,384,445 | 6,856,592 | 507,821 | 78.05% | Passed |
| 2025 | 2025-06-27 | 15,086,368 | 1,856,643 | 615,511 | 89.04% | Passed |
| 2024 | 2024-06-06 | 15,849,545 | 6,977,695 | 468,294 | 69.43% | Passed |
| 2023 | 2023-06-23 | 20,792,271 | 2,594,301 | 405,177 | 88.91% | Passed |
| 2020 | 2020-06-05 | 25,967,469 | 1,316,736 | 603,553 | 95.17% | Passed |
| 2017 | 2017-06-22 | 16,084,478 | 3,980,923 | 364,111 | 80.16% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-18 | 78.05%a |
| 2025 | 2025-06-27 | 89.04%b |
| 2024 | 2024-06-06 | 69.43%c |
a. Approved under the standard stated in the filing — “Accordingly, abstentions will not affect the determination of the directors who have received the highest number of affirmative votes or whether the votes cast in favor of Proposals 2, 3 or 4 exceed those cast against each such proposal.”.
b. Approved under the standard stated in the filing — “Accordingly, abstentions will not affect the determination of the directors who have received the highest number of affirmative votes or whether the votes cast in favor of Proposals 2 or 3 exceed those cast against each such proposal.”.
c. Approved under the standard stated in the filing — “Accordingly, abstentions will not affect the determination of the directors who have received the highest number of affirmative votes or whether the votes cast in favor of Proposals 2 or 3 exceed those cast against each such proposal.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 21.8 : 1 |
|---|---|
| CEO total compensation | $4,178,008 |
| Median employee compensation | $191,656 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Thomas J. Cable | Director | 2026-05-22 | D | 7,500 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas J. Cable | Director | 2026-05-22 | D | 7,500 | 12 | 87,039 | Common | Form 4 ↗ |
| Thomas J. Cable | Director | 2026-05-22 | A | 7,500 | 11 | 81,300 | Common | Form 4 ↗ |
| Rajiv Shah | Director | 2026-06-18 | A | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gregory Demopulos | Director | 2026-06-18 | A | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas J. Cable | Director | 2026-06-18 | A | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Arnold C. Hanish | Director | 2026-06-18 | A | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Leroy E. Hood MD PhD | Director | 2026-06-18 | A | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Diana T. Perkinson | Director | 2026-06-18 | A | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas F. Bumol | Director | 2026-06-18 | A | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gregory Demopulos | Director | 2026-07-22 | A | 1,000,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Peter Cancelmo | VP, General Counsel | 2026-07-22 | A | 105,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Borges | VP, Finance & CAO | 2026-07-22 | A | 105,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph L. Schocken | Director | 2026-08-12 | A | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Borges | VP, Finance & CAO | 2026-08-13 | D | 5,000 | 17 | 84,750 | Common | Form 4 ↗ |
| David Borges | VP, Finance & CAO | 2026-08-13 | A | 5,000 | 4 | 19,650 | Common | Form 4 ↗ |
| David Borges | VP, Finance & CAO | 2026-08-13 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas J. Cable | Director | 2026-08-20 | D | 7,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas J. Cable | Director | 2026-08-20 | A | 7,500 | 4 | 29,475 | Common | Form 4 ↗ |
| Thomas J. Cable | Director | 2026-08-20 | D | 15,000 | 18 | 276,773 | Common | Form 4 ↗ |
| Thomas J. Cable | Director | 2026-08-20 | D | 7,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas J. Cable | Director | 2026-08-20 | A | 7,500 | 2 | 15,000 | Common | Form 4 ↗ |
| David Borges | VP, Finance & CAO | 2026-08-21 | A | 5,906 | 4 | 23,211 | Common | Form 4 ↗ |
| David Borges | VP, Finance & CAO | 2026-08-21 | D | 5,906 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Borges | VP, Finance & CAO | 2026-08-21 | A | 4,094 | 3 | 12,036 | Common | Form 4 ↗ |
| David Borges | VP, Finance & CAO | 2026-08-21 | D | 4,094 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Borges | VP, Finance & CAO | 2026-08-21 | D | 10,000 | 19 | 189,500 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-08-24 | — | 906 | — | — | 1 insider, 1 accrual row | ||
| David Borges | VP, Finance & CAO | 2026-08-24 | A | 906 | 3 | 2,664 | Common | Form 4 ↗ |
| David Borges | VP, Finance & CAO | 2026-08-24 | D | 906 | 19 | 17,305 | Common | Form 4 ↗ |
| Arnold C. Hanish | Director | 2026-08-26 | A | 5,000 | 16 | 79,050 | Common | Form 4 ↗ |
| Arnold C. Hanish | Director | 2026-08-26 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Arnold C. Hanish | Director | 2026-08-26 | D | 5,000 | 19 | 92,633 | Common | Form 4 ↗ |
| Arnold C. Hanish | Director | 2026-08-27 | D | 5,000 | 19 | 94,381 | Common | Form 4 ↗ |
| Arnold C. Hanish | Director | 2026-08-27 | A | 7,500 | 15 | 109,950 | Common | Form 4 ↗ |
| Arnold C. Hanish | Director | 2026-08-27 | D | 7,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Arnold C. Hanish | Director | 2026-08-27 | D | 2,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Arnold C. Hanish | Director | 2026-08-27 | D | 5,000 | 19 | 95,081 | Common | Form 4 ↗ |
| Arnold C. Hanish | Director | 2026-08-27 | A | 2,500 | 16 | 39,525 | Common | Form 4 ↗ |
| Peter Cancelmo | VP, General Counsel | 2026-08-28 | D | 25,000 | 19 | 466,128 | Common | Form 4 ↗ |
| Peter Cancelmo | VP, General Counsel | 2026-08-28 | D | 25,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Peter Cancelmo | VP, General Counsel | 2026-08-28 | A | 25,000 | 3 | 73,500 | Common | Form 4 ↗ |
| Peter Cancelmo | VP, General Counsel | 2026-08-31 | D | 25,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Peter Cancelmo | VP, General Counsel | 2026-08-31 | D | 25,000 | 19 | 463,540 | Common | Form 4 ↗ |
| Peter Cancelmo | VP, General Counsel | 2026-08-31 | A | 25,000 | 3 | 73,500 | Common | Form 4 ↗ |
| David Borges | VP, Finance & CAO | 2026-09-22 | A | 5,000 | 3 | 14,700 | Common | Form 4 ↗ |
| David Borges | VP, Finance & CAO | 2026-09-22 | A | 5,000 | 4 | 19,650 | Common | Form 4 ↗ |
| David Borges | VP, Finance & CAO | 2026-09-22 | D | 10,000 | 21 | 209,500 | Common | Form 4 ↗ |
| David Borges | VP, Finance & CAO | 2026-09-22 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Borges | VP, Finance & CAO | 2026-09-22 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Borges | VP, Finance & CAO | 2026-09-23 | D | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Borges | VP, Finance & CAO | 2026-09-23 | D | 10,000 | 21 | 209,500 | Common | Form 4 ↗ |
| David Borges | VP, Finance & CAO | 2026-09-23 | A | 10,000 | 16 | 155,800 | Common | Form 4 ↗ |
| Gregory Demopulos | Director | 2026-10-28 | A | 500,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
View all 54 transactions
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Thomas J. Cable | Director | 2026-05-22 | D | 7,500 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas J. Cable | Director | 2026-05-22 | D | 7,500 | 12 | 87,039 | Common | Form 4 ↗ |
| Thomas J. Cable | Director | 2026-05-22 | A | 7,500 | 11 | 81,300 | Common | Form 4 ↗ |
| Rajiv Shah | Director | 2026-06-18 | A | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gregory Demopulos | Director | 2026-06-18 | A | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas J. Cable | Director | 2026-06-18 | A | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Arnold C. Hanish | Director | 2026-06-18 | A | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Leroy E. Hood MD PhD | Director | 2026-06-18 | A | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Diana T. Perkinson | Director | 2026-06-18 | A | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas F. Bumol | Director | 2026-06-18 | A | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gregory Demopulos | Director | 2026-07-22 | A | 1,000,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Peter Cancelmo | VP, General Counsel | 2026-07-22 | A | 105,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Borges | VP, Finance & CAO | 2026-07-22 | A | 105,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph L. Schocken | Director | 2026-08-12 | A | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Borges | VP, Finance & CAO | 2026-08-13 | D | 5,000 | 17 | 84,750 | Common | Form 4 ↗ |
| David Borges | VP, Finance & CAO | 2026-08-13 | A | 5,000 | 4 | 19,650 | Common | Form 4 ↗ |
| David Borges | VP, Finance & CAO | 2026-08-13 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas J. Cable | Director | 2026-08-20 | D | 7,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas J. Cable | Director | 2026-08-20 | A | 7,500 | 4 | 29,475 | Common | Form 4 ↗ |
| Thomas J. Cable | Director | 2026-08-20 | D | 15,000 | 18 | 276,773 | Common | Form 4 ↗ |
| Thomas J. Cable | Director | 2026-08-20 | D | 7,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas J. Cable | Director | 2026-08-20 | A | 7,500 | 2 | 15,000 | Common | Form 4 ↗ |
| David Borges | VP, Finance & CAO | 2026-08-21 | A | 5,906 | 4 | 23,211 | Common | Form 4 ↗ |
| David Borges | VP, Finance & CAO | 2026-08-21 | D | 5,906 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Borges | VP, Finance & CAO | 2026-08-21 | A | 4,094 | 3 | 12,036 | Common | Form 4 ↗ |
| David Borges | VP, Finance & CAO | 2026-08-21 | D | 4,094 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Borges | VP, Finance & CAO | 2026-08-21 | D | 10,000 | 19 | 189,500 | Common | Form 4 ↗ |
| David Borges | VP, Finance & CAO | 2026-08-24 | D | 906 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Borges | VP, Finance & CAO | 2026-08-24 | A | 906 | 3 | 2,664 | Common | Form 4 ↗ |
| David Borges | VP, Finance & CAO | 2026-08-24 | D | 906 | 19 | 17,305 | Common | Form 4 ↗ |
| Arnold C. Hanish | Director | 2026-08-26 | A | 5,000 | 16 | 79,050 | Common | Form 4 ↗ |
| Arnold C. Hanish | Director | 2026-08-26 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Arnold C. Hanish | Director | 2026-08-26 | D | 5,000 | 19 | 92,633 | Common | Form 4 ↗ |
| Arnold C. Hanish | Director | 2026-08-27 | D | 5,000 | 19 | 94,381 | Common | Form 4 ↗ |
| Arnold C. Hanish | Director | 2026-08-27 | A | 7,500 | 15 | 109,950 | Common | Form 4 ↗ |
| Arnold C. Hanish | Director | 2026-08-27 | D | 7,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Arnold C. Hanish | Director | 2026-08-27 | D | 2,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Arnold C. Hanish | Director | 2026-08-27 | D | 5,000 | 19 | 95,081 | Common | Form 4 ↗ |
| Arnold C. Hanish | Director | 2026-08-27 | A | 2,500 | 16 | 39,525 | Common | Form 4 ↗ |
| Peter Cancelmo | VP, General Counsel | 2026-08-28 | D | 25,000 | 19 | 466,128 | Common | Form 4 ↗ |
| Peter Cancelmo | VP, General Counsel | 2026-08-28 | D | 25,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Peter Cancelmo | VP, General Counsel | 2026-08-28 | A | 25,000 | 3 | 73,500 | Common | Form 4 ↗ |
| Peter Cancelmo | VP, General Counsel | 2026-08-31 | D | 25,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Peter Cancelmo | VP, General Counsel | 2026-08-31 | D | 25,000 | 19 | 463,540 | Common | Form 4 ↗ |
| Peter Cancelmo | VP, General Counsel | 2026-08-31 | A | 25,000 | 3 | 73,500 | Common | Form 4 ↗ |
| David Borges | VP, Finance & CAO | 2026-09-22 | A | 5,000 | 3 | 14,700 | Common | Form 4 ↗ |
| David Borges | VP, Finance & CAO | 2026-09-22 | A | 5,000 | 4 | 19,650 | Common | Form 4 ↗ |
| David Borges | VP, Finance & CAO | 2026-09-22 | D | 10,000 | 21 | 209,500 | Common | Form 4 ↗ |
| David Borges | VP, Finance & CAO | 2026-09-22 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Borges | VP, Finance & CAO | 2026-09-22 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Borges | VP, Finance & CAO | 2026-09-23 | D | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Borges | VP, Finance & CAO | 2026-09-23 | D | 10,000 | 21 | 209,500 | Common | Form 4 ↗ |
| David Borges | VP, Finance & CAO | 2026-09-23 | A | 10,000 | 16 | 155,800 | Common | Form 4 ↗ |
| Gregory Demopulos | Director | 2026-10-28 | A | 500,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Sources (90 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Gregory Demopulos. DEF 14A, filed 2026-04-30. Section “Executive Compensation” · page 37. As printed: 4,178,008. View filing ↗
- Section 01, Peter Cancelmo. DEF 14A, filed 2026-04-30. Section “Executive Compensation”. As printed: 920,702. View filing ↗
- Section 01, David Borges. DEF 14A, filed 2026-04-30. Section “Executive Compensation”. As printed: 686,274. View filing ↗
- Section 03, Gregory Demopulos OPTION. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, David Borges OPTION. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Peter Cancelmo OPTION. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-30. Section “CEO Pay Ratio”. As printed: 21.8 : 1. View filing ↗
- Section 08, Thomas J. Cable. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 151,060. View filing ↗
- Section 08, Rajiv Shah, M.D. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 113,560. View filing ↗
- Section 08, Arnold C. Hanish. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 111,060. View filing ↗
- Section 08, Leroy E. Hood, M.D., Ph.D. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 108,560. View filing ↗
- Section 08, Thomas F. Bumol, Ph.D. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 101,060. View filing ↗
- Section 08, Diana T. Perkinson, M.D. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 101,060. View filing ↗
- Section 08, Peter A. Demopulos, M.D. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 96,060. View filing ↗
- Section 08, Gregory A. Demopulos, M.D. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Thomas J. Cable 2026-05-22. Form 4, filed 2026-05-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas J. Cable 2026-05-22. Form 4, filed 2026-05-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas J. Cable 2026-05-22. Form 4, filed 2026-05-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rajiv Shah 2026-06-18. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gregory Demopulos 2026-06-18. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas J. Cable 2026-06-18. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Arnold C. Hanish 2026-06-18. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Leroy E. Hood MD PhD 2026-06-18. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Diana T. Perkinson 2026-06-18. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas F. Bumol 2026-06-18. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gregory Demopulos 2026-07-22. Form 4, filed 2026-07-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Peter Cancelmo 2026-07-22. Form 4, filed 2026-07-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Borges 2026-07-22. Form 4, filed 2026-07-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph L. Schocken 2026-08-12. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Borges 2026-08-13. Form 4, filed 2026-08-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Borges 2026-08-13. Form 4, filed 2026-08-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Borges 2026-08-13. Form 4, filed 2026-08-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas J. Cable 2026-08-20. Form 4, filed 2026-08-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas J. Cable 2026-08-20. Form 4, filed 2026-08-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas J. Cable 2026-08-20. Form 4, filed 2026-08-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas J. Cable 2026-08-20. Form 4, filed 2026-08-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas J. Cable 2026-08-20. Form 4, filed 2026-08-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Borges 2026-08-21. Form 4, filed 2026-08-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Borges 2026-08-21. Form 4, filed 2026-08-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Borges 2026-08-21. Form 4, filed 2026-08-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Borges 2026-08-21. Form 4, filed 2026-08-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Borges 2026-08-21. Form 4, filed 2026-08-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Borges 2026-08-24. Form 4, filed 2026-08-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Borges 2026-08-24. Form 4, filed 2026-08-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Borges 2026-08-24. Form 4, filed 2026-08-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Arnold C. Hanish 2026-08-26. Form 4, filed 2026-08-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Arnold C. Hanish 2026-08-26. Form 4, filed 2026-08-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Arnold C. Hanish 2026-08-26. Form 4, filed 2026-08-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Arnold C. Hanish 2026-08-27. Form 4, filed 2026-08-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Arnold C. Hanish 2026-08-27. Form 4, filed 2026-08-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Arnold C. Hanish 2026-08-27. Form 4, filed 2026-08-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Arnold C. Hanish 2026-08-27. Form 4, filed 2026-08-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Arnold C. Hanish 2026-08-27. Form 4, filed 2026-08-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Arnold C. Hanish 2026-08-27. Form 4, filed 2026-08-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Peter Cancelmo 2026-08-28. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Peter Cancelmo 2026-08-28. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Peter Cancelmo 2026-08-28. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Peter Cancelmo 2026-08-31. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Peter Cancelmo 2026-08-31. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Peter Cancelmo 2026-08-31. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Borges 2026-09-22. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Borges 2026-09-22. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Borges 2026-09-22. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Borges 2026-09-22. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Borges 2026-09-22. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Borges 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Borges 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Borges 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gregory Demopulos 2026-10-28. Form 4, filed 2026-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-25. Item 5.07 · say-on-pay result. As reported: 78.05% (votes for as printed: 24,384,445). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-07-02. Item 5.07 · say-on-pay result. As reported: 89.04% (votes for as printed: 15,086,368). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-12. Item 5.07 · say-on-pay result. As reported: 69.43% (votes for as printed: 15,849,545). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 495,000 + equity 0 + all other 0 = 495,000, summed across the director compensation table rows.
- Pacira BioSciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Pacira BioSciences, Inc.'s own proxy. As printed: 11,636,917. View filing ↗
- Arcus Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Arcus Biosciences, Inc.'s own proxy. As printed: 9,656,813. View filing ↗
- Agios Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Agios Pharmaceuticals, Inc.'s own proxy. As printed: 5,370,389. View filing ↗
- Omeros Corp (subject), Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Omeros Corp's own proxy. As printed: 4,178,008. View filing ↗
- Vanda Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Vanda Pharmaceuticals, Inc.'s own proxy. As printed: 3,851,468. View filing ↗
- Esperion Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-16. CEO total compensation as printed in Esperion Therapeutics, Inc.'s own proxy. As printed: 3,535,512. View filing ↗
- Aclaris Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Aclaris Therapeutics, Inc.'s own proxy. As printed: 3,375,591. View filing ↗
- Enanta Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-01-26. CEO total compensation as printed in Enanta Pharmaceuticals, Inc.'s own proxy. As printed: 2,769,548. View filing ↗
- Coherus BioSciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in Coherus BioSciences, Inc.'s own proxy. As printed: 2,736,874. View filing ↗
- Karyopharm Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-13. CEO total compensation as printed in Karyopharm Therapeutics's own proxy. As printed: 2,320,902. View filing ↗
- Ironwood Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Ironwood Pharmaceuticals, Inc.'s own proxy. As printed: 1,948,390. View filing ↗
- Collegium Pharmaceutical,, Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Collegium Pharmaceutical,'s own proxy. As printed: 1,715,846. View filing ↗
- Mersana Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-29. CEO total compensation as printed in Mersana Therapeutics, Inc.'s own proxy. As printed: 1,613,754. View filing ↗
- Section 10a, Esperion Therapeutics, Inc. reciprocity. DEF 14A. Esperion Therapeutics, Inc. names Omeros Corp in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Vanda Pharmaceuticals, Inc. reciprocity. DEF 14A. Vanda Pharmaceuticals, Inc. names Omeros Corp in its own disclosed peer group (read from its most recent proxy). View filing ↗